Inventor · disambiguated record
James William West
Also filed as: SAGERT JASON · WEST JAMES W · WEST JAMES WILLIAM
48 granted patents·15 pending applications·1,186 citations·filing 2008–2024
99Inventor score
Files withCYTOMX THERAPEUTICS INC45BRISTOL MYERS SQUIBB CO4UNIV CALIFORNIA4STAGLIANO NANCY E3CYTOMX THERAPETUICS INC2
Top patents by PatentIndex Score
63 records- 0198US10875913B2Methods of treatment using activatable anti-EGFR antibodiesCYTOMX THERAPEUTICS INC·Filed 2018·Granted Dec 29, 2020·21 cites·40 claims
- 0298US10118961B2Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWVCYTOMX THERAPEUTICS INC·Filed 2016·Granted Nov 6, 2018·34 cites·13 claims
- 0398US10077300B2Activatable binding polypeptides and methods of identification and use thereofUNIV CALIFORNIA·Filed 2015·Granted Sep 18, 2018·42 cites·36 claims
- 0498US10059762B2Anti-EGFR activatable antibodiesCYTOMX THERAPEUTICS INC·Filed 2016·Granted Aug 28, 2018·42 cites·41 claims
- 0598US9644016B2Soluble notch receptor proproteins and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted May 9, 2017·34 cites·28 claims
- 0698US9309510B2Protease-resistant systems for polypeptide display and methods of making and using thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Apr 12, 2016·26 cites·37 claims
- 0798US8541203B2Activatable binding polypeptides and methods of identification and use thereofDAUGHERTY PATRICK SEAN·Filed 2012·Granted Sep 24, 2013·73 cites·41 claims
- 0898US8513390B2Modified antibody compositions, methods of making and using thereofSTAGLIANO NANCY E·Filed 2012·Granted Aug 20, 2013·111 cites·137 claims
- 0997US10745481B2Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Aug 18, 2020·22 cites·88 claims
- 1097US10709799B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Jul 14, 2020·10 cites·31 claims
- 1197US9889211B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Feb 13, 2018·29 cites·52 claims
- 1297US9169321B2Activatable binding polypeptides and methods of identification and use thereofUNIV CALIFORNIA·Filed 2013·Granted Oct 27, 2015·62 cites·41 claims
- 1397US9127053B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Sep 8, 2015·39 cites·33 claims
- 1497US9120853B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Sep 1, 2015·52 cites·43 claims
- 1597US8563269B2Modified antibody compositions, methods of making and using thereofSTAGLIANO NANCY E·Filed 2011·Granted Oct 22, 2013·119 cites·38 claims
- 1697US8529898B2Activatable binding polypeptides and methods of identification and use thereofDAUGHERTY PATRICK SEAN·Filed 2012·Granted Sep 10, 2013·64 cites·29 claims
- 1797US8399219B2Protease activatable interferon alpha proproteinSTAGLIANO NANCY E·Filed 2010·Granted Mar 19, 2013·46 cites·17 claims
- 1896US9545442B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jan 17, 2017·19 cites·57 claims
- 1996US9453078B2Modified antibody compositions, methods of making and using thereofCYTOMX THERAPETUICS INC·Filed 2013·Granted Sep 27, 2016·64 cites·28 claims
- 2096US8993266B2Proproteins activatable interferon alphaCYTOMX THERAPEUTICS INC·Filed 2012·Granted Mar 31, 2015·28 cites·14 claims
- 2196US8518404B2Activatable binding polypeptides and methods of identification and use thereofDAUGHERTY PATRICK·Filed 2012·Granted Aug 27, 2013·105 cites·25 claims
- 2295US11753466B2Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Sep 12, 2023·7 cites·64 claims
- 2395US10669339B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Jun 2, 2020·10 cites·44 claims
- 2495US10513549B2Cleavage-activatable interferon-alpha proproteinCYTOMX THERAPEUTICS INC·Filed 2017·Granted Dec 24, 2019·14 cites·11 claims
- 2595US10301380B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2017·Granted May 28, 2019·17 cites·29 claims
- 2695US9487590B2Activatable antibodies that bind interleukin-6 receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Nov 8, 2016·15 cites·35 claims
- 2794US11028162B2Methods for manufacturing activatable binding polypeptides comprising matrix metalloprotease cleavable moietiesUNIV CALIFORNIA·Filed 2018·Granted Jun 8, 2021·6 cites·27 claims
- 2894US10336824B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jul 2, 2019·16 cites·48 claims
- 2993US11890354B2Activatable antibodies that bind epidermal growth factor receptor and methods thereofCYTOMX THERAPEUTICS INC·Filed 2020·Granted Feb 6, 2024·2 cites·16 claims
- 3093US9688748B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jun 27, 2017·11 cites·39 claims
- 3192US10513558B2Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Dec 24, 2019·23 cites·77 claims
- 3291US11046759B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jun 29, 2021·4 cites·58 claims
- 3390US12502439B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Granted Dec 23, 2025·0 cites·20 claims
- 3490US11161906B2Multispecific antibodies, multispecific activatable antibodies and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2014·Granted Nov 2, 2021·12 cites·45 claims
- 3590US2024228603A1Modified antibody compositions, methods of making and using thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3689US2025034755A1Protease-resistant systems for polypeptide display and methods of making and using thereofCYTOMX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3786US12459999B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Granted Nov 4, 2025·0 cites·8 claims
- 3886US12441799B2Activatable anti-CTLA-4 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Oct 14, 2025·1 cites·14 claims
- 3985US2023183308A1Proproteins and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4084US10611845B2Activatable antibodies that bind interleukin-6 receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Apr 7, 2020·2 cites·35 claims
- 4182US11174316B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Nov 16, 2021·1 cites·19 claims
- 4281US2023035290A1Proproteins and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4380US11117968B2Activatable anti-CTLA-4 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Sep 14, 2021·2 cites·20 claims
- 4479US12209120B2Activatable anti-VEGF scFvUNIV CALIFORNIA·Filed 2021·Granted Jan 28, 2025·0 cites·3 claims
- 4579US12139816B2Protease-resistant systems for polypeptide display and methods of making and using thereofCYTOMX THERAPEUTICS INC·Filed 2021·Granted Nov 12, 2024·0 cites·9 claims
- 4679US11548943B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2021·Granted Jan 10, 2023·0 cites·9 claims
- 4779US11472875B1Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2021·Granted Oct 18, 2022·0 cites·11 claims
- 4878US11548944B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2021·Granted Jan 10, 2023·0 cites·10 claims
- 4978US11306149B2Anti-CD40 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 19, 2022·1 cites·20 claims
- 5078US2024076374A1Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 63 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when James William West files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →